Heart outcomes and complications
Cardiovascular events and heart-failure symptoms ask different questions. Diabetic eye complications bring another organ into the heart account.
SELECT enrolment
The SELECT trial enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke versus placebo: hazard ratio 0.80, with a 95% confidence interval of 0.72-0.90. The report describes a 20% relative risk reduction.
Established cardiovascular disease is a decisive part of that sentence. These participants already had the condition around which the trial’s question was built. Its result deserves attention on those terms. The composite also makes me wonder where an organ account should end: death, heart attack and stroke already give it several clinical subjects.
A composite gathers several events into the trial’s main measure. In SELECT, death from cardiovascular causes, a nonfatal heart attack and a nonfatal stroke contribute to that measure. The result gives a reason to take the medicine’s cardiovascular research seriously within this population; it leaves the broader question of benefit in an otherwise unspecified crowd for another investigation.
Diabetic retinopathy
A different group appears in SUSTAIN-6: 3,297 people with type 2 diabetes at high cardiovascular risk. Semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, with a hazard ratio of 0.74 and a 95% confidence interval of 0.58-0.95. Diabetic-retinopathy complications were more frequent, with a hazard ratio of 1.76 and a 95% confidence interval of 1.11-2.78.
The eye finding makes a tidy celebration impossible for me. It sits inside a trial with a beneficial cardiovascular result, among people whose diabetes matters to both parts of the account. A summary devoted entirely to the heart would lose a consequential piece of their experience.
The safety review discusses retinopathy monitoring with rapid glycemic correction. That clinical setting deserves exact attention. The research becomes more useful when the condition and the complication stay visible together.
Heart failure with preserved ejection fraction
The STEP-HFpEF trial studied people with obesity-related heart failure with preserved ejection fraction. Semaglutide improved heart-failure-related symptoms and physical limitations, measured using the KCCQ score, and produced greater weight loss than placebo.
Here the attraction is the attention paid to symptoms and limitations. That question deserves its place even before a weight result appears. It asks about the burden of a particular form of heart failure, while SELECT asks about cardiovascular events in its own defined population. Combining their favourable findings into a single heart-health slogan would discard much of what makes each paper interesting.
The kidney trial brings the heart into another organ’s result: cardiovascular death contributes to its primary composite. It concerns people with both diabetes and chronic kidney disease.